DLD Asset Management, LP - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 47 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
DLD Asset Management, LP ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2019$29,820,000
-0.8%
30,000,000
-7.7%
1.10%
-46.7%
Q4 2018$30,048,000
+56.4%
32,500,000
+71.1%
2.06%
+116.7%
Q3 2018$19,218,000
+118.5%
19,000,000
+90.0%
0.95%
+43.5%
Q2 2018$8,794,00010,000,0000.66%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2018
NameSharesValueWeighting ↓
Worth Venture Partners, LLC 5,324,000$4,995,0003.78%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 57,791,000$53,020,0002.12%
DLD Asset Management, LP 32,500,000$30,048,0002.06%
Castle Creek Arbitrage, LLC 4,504,000$4,161,0001.43%
TENOR CAPITAL MANAGEMENT Co., L.P. 10,000,000$9,372,0000.62%
Graham Capital Management, L.P. 14,636,000$13,509,0000.60%
OAKTREE CAPITAL MANAGEMENT LP 64,452,000$59,704,0000.54%
Context Capital Management, LLC 1,000,000$926,0000.52%
ADVENT CAPITAL MANAGEMENT /DE/ 23,118,000$21,341,0000.52%
WOLVERINE ASSET MANAGEMENT LLC 18,583,000$17,322,0000.21%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders